Dedicated to providing innovative research based products of the highest quality for animals and humans.

News & Events

Envision leadership in the Pharmateutical & Animal Healthcare Markets, through advanced product innovation and strategic alliance

News & Events

A Prospective Study on the Use of Multistrain Probiotics as an Adjunct in the Treatment of Neonatal Pneumonia in a Tertiary Government Hospital

Date: November 05, 2012

By: Herbee Manaligod, M.D., Jennie Wong M.D., Jennifer Roamar M.D.
     
Introduction: Neonatal pneumonia ranks third as a cause of infant mortality with a rate of 9.3 % in 2005 and the leading cause of morbidity in 2004 in the Philippines. The discovery of a Multistrain Probiotic (Protexin Restore) has been shown to be generally safe for human consumption and has its benefits in cases of acute gastroenteritis, Irritable bowel syndrome, Ulcerative colitis, and Necrotizing entrocolitis among neonates and Pneumonia in older children. However, its use in Neonatal pneumonia have not yet been documented, hence the author embarked on this study.
 
Objective:  To determine the effect of a Multistrain Probiotic(Protexin Restore) as adjunct in the treatment of neonatal pneumonia
 
Setting: Tertiary government hospital (Ospital ng Maynila Medical Center)
 
Subjects:  Neonates 0-28 days admitted at the NICU and Ward with Neonatal pneumonia were included in this study. Prematures (<35 weeks AOG) and patients diagnosed with sepsis neonatorum, and those needing ventilatory support or surgical intervention were excluded in the study.
Research Design: Randomized controlled trial, open label
 
Methodology: Patients were randomly selected by lottery and divided into two groups: Group A (control group), received conventional treatment and IV antibiotics. Group B (treatment group) received conventional treatment, IV antibiotics plus one sachet of Multistrain Probiotics (Restore) per day. The following parameters were measured: progression of respiratory distress such as retractions, tachypnea, alar flaring, feeding tolerance as well as progression to sepsis, length of hospital stay and other complications.
 
Results: There were 30 subjects in the study, 15 subjects in each group. Statistical analysis using chi square test showed significant difference between the 2 groups based on the progression of respiratory distress, with the experimental group having shorter duration of tachypnea, alar flaring, retractions, early feeding tolerance and a shortened hospital stay at the NICU and pediatric wards. A less number of patients in the experimental group progressed to sepsis. There was no significant difference in terms of complications of pneumonia in both groups.
 
Conclusion: The use of probiotics in neonates with pneumonia can decrease the signs and symptoms of respiratory distress and shortened their hospital stay as well as progression to sepsis
 
Protexin Restore is recommended at One sachet daily after meal for 5 to 7 days or as needed. Can be added to feed, water, milk or juice. 1 billion CFU/sachet (Colony Forming Unit). Protexin Vitality chewable tablet, is ideal for school children more than 4 years old.

Connect with Us

Prebiotech on Facebook Prebiotech on Twitter Prebiotech on LinkedIn Prebiotech on YouTube Prebiotech on Google+

Copyright © 2019. Prebiotech Health Care.
All rights reserved